Sutro Biopharma Presents Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer at the 2020 IGCS Annual Global MeetingPRNewsWire • 09/09/20
Sutro Biopharma Announces Promising STRO-002 Interim Phase 1 Clinical Data in Ovarian Cancer and Presentation at the 2020 IGCS Annual Global MeetingPRNewsWire • 09/02/20
Sutro Biopharma Earns Clinical Supply Milestone Payment from Merck KGaA, Darmstadt, Germany for Novel Bispecific Antibody Drug Conjugate Targeting Solid TumorsPRNewsWire • 08/25/20
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferencePRNewsWire • 08/10/20
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor ImmunityPRNewsWire • 06/22/20
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020PRNewsWire • 06/09/20
Sutro Biopharma Expands Senior Management with the Additions of Vice President of Clinical Development and Vice President of Finance and ControllerPRNewsWire • 05/21/20
Sutro Biopharma Adds Two Exceptional Leaders to Advisory Boards-- Carlos Paya, MD, PhD, and Lainie Martin, MDPRNewsWire • 05/21/20
Sutro Biopharma Announces Closing of $98.0 Million Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional SharesPRNewsWire • 05/14/20
Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/16/20
Sutro Biopharma's Platform Technology Makes It A Promising Oncology Pick For 2020Seeking Alpha • 01/27/20
